Skip to main content
Top

01-11-2017 | Breast cancer | Article

Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy

Journal: Annals of Surgical Oncology

Authors: James Laird, BS, Benjamin Lok, MD, Chun Siu, BS, Oren Cahlon, MD, Atif J. Khan, MD, Beryl McCormick, MD, Simon N. Powell, MD, PhD, Hiram Cody, MD, Hannah Yong Wen, MD, PhD, Alice Ho, MD, Lior Z. Braunstein, MD

Publisher: Springer International Publishing

Abstract

Background

Among all in-breast tumor recurrences (IBTR) following breast-conserving therapy (BCT), some comprise metachronous new primaries (NPs) while others are true recurrences (TRs). Establishing this distinction remains a challenge.

Methods

We studied 3932 women who underwent BCT for stage I–III breast cancer from 1998 to 2008. Of these, 115 (2.9%) had an IBTR. Excluding patients with inoperable/unresectable recurrences or simultaneous distant metastases, 81 patients with isolated IBTR comprised the study population. An IBTR was categorized as an NP rather than a TR if it included an in situ component. The log-rank test and Kaplan–Meier method were used to evaluate disease-free survival (DFS) and overall survival (OS), and univariate and multivariate analyses were performed using Cox proportional hazards regression models.

Results

At a median of 64.5 months from IBTR diagnosis, 28 of 81 patients had DFS events. Five-year DFS was 43.1% in the TR group (p = 0.0001) versus 80.3% in the NP group, while 5-year OS was 59.7% in the TR group versus 91.7% among those with NPs (p = 0.0011). On univariate analysis, increasing tumor size, high grade, positive margins, lymphovascular invasion, node involvement, lack of axillary surgery, chemotherapy, radiation therapy, and IBTR type (TR vs. NP) were significantly associated with worse DFS. Controlling for tumor size and margin status, TRs remained significantly associated with lower DFS (hazard ratio 3.717, 95% confidence interval 1.607–8.595, p = 0.002).

Conclusion

The presence of an in situ component is associated with prognosis among patients with IBTR following BCT and may be useful in differentiating TRs and NPs.
Literature
1.
Early Breast Cancer Trialists’ Collaborative Group, Darby S, McGale P, et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707-16CrossRef
2.
Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24:2028-37CrossRefPubMed
3.
Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27:2466-73CrossRefPubMedPubMedCentral
4.
Clemons M, Danson S, Hamilton T, et al. Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev. 2001;27:67-82CrossRefPubMed
5.
Haffty BG, Reiss M, Beinfield M, et al. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol. 1996;14:52-7CrossRefPubMed
6.
van Laar C, van der Sangen MJ, Poortmans PM, et al. Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer. 2013;49:3093-101CrossRefPubMed
7.
Braunstein LZ, Niemierko A, Shenouda MN, et al. Outcome Following Local-Regional Recurrence in Women with Early-Stage Breast Cancer: Impact of Biologic Subtype. Breast J. 2015;21(2):161–7CrossRefPubMed
8.
Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011;29:3885-91CrossRefPubMedPubMedCentral
9.
Truong PT, Sadek BT, Lesperance MF, et al. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy? Int J Radiat Oncol Biol Phys. 2014;88:57-64CrossRefPubMed
10.
Voogd AC, van Oost FJ, Rutgers EJ, et al: Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer. 2005;41:2637-44CrossRefPubMed
11.
Fredriksson I, Liljegren G, Arnesson LG, et al. Local recurrence in the breast after conservative surgery–a study of prognosis and prognostic factors in 391 women. Eur J Cancer. 2002;38:1860-70CrossRefPubMed
12.
Alpert TE, Kuerer HM, Arthur DW, et al. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys. 2005;63:845-51CrossRefPubMed
13.
Smith TE, Lee D, Turner BC, et al. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000;48:1281-9CrossRefPubMed
14.
Krauss DJ, Kestin LL, Mitchell C, et al. Changes in temporal patterns of local failure after breast-conserving therapy and their prognostic implications. Int J Radiat Oncol Biol Phys. 2004;60:731-40CrossRefPubMed
15.
Komoike Y, Akiyama F, Iino Y, et al. Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer. 2005;12:104-11CrossRefPubMed
16.
Fodor J, Major T, Polgar C, et al. Prognosis of patients with local recurrence after mastectomy or conservative surgery for early-stage invasive breast cancer. Breast. 2008;17:302-8CrossRefPubMed
17.
Abd-Alla HM, Lotayef MM, Abou Bakr A, et al. Ipsilateral in-breast tumor relapse after breast conservation therapy: true recurrence versus new primary tumor. J Egypt Natl Canc Inst. 2006;18:183-90PubMed
18.
Yi M, Buchholz TA, Meric-Bernstam F, et al. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011;253:572-9CrossRefPubMedPubMedCentral
19.
Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002;95:2059-67CrossRefPubMed
20.
Panet-Raymond V, Truong PT, McDonald RE, et al. True recurrence versus new primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2011;81:409-17CrossRefPubMed
21.
21. Nishimura S, Takahashi K, Akiyama F, et al. Classification of ipsilateral breast tumor recurrence after breast-conserving therapy: new primary cancer allows a good prognosis. Breast Cancer. 2005;12:112-7CrossRefPubMed
22.
Sakai T, Nishimura S, Ogiya A, et al. Four types of ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: classification of IBTR based on precise pathological examination. Pathol Int. 2015;65:113-8CrossRefPubMed
23.
Silverberg SG, Chitale AR. Assessment of significance of proportions of intraductal and infiltrating tumor growth in ductal carcinoma of the breast. Cancer. 1973;32:830-7CrossRefPubMed
24.
Fisher ER, Gregorio RM, Fisher B, et al. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975;36:1-85CrossRefPubMed
25.
Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008;14:370-8CrossRefPubMed
26.
Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31:417-26CrossRefPubMed
27.
Gupta SK, Douglas-Jones AG, Fenn N, et al. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer. 1997;80:1740-5CrossRefPubMed
28.
Buerger H, Otterbach F, Simon R, et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 1999;189:521-6CrossRefPubMed
29.
Burkhardt L, Grob TJ, Hermann I, et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2010;123:757-65CrossRefPubMed
30.
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-95CrossRefPubMedPubMedCentral
31.
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-45CrossRefPubMed
32.
Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25:2127-32CrossRefPubMed
33.
Yoshida T, Takei H, Kurosumi M, et al. True recurrences and new primary tumors have different clinical features in invasive breast cancer patients with ipsilateral breast tumor relapse after breast-conserving treatment. Breast J. 2010;16:127-33CrossRefPubMed
34.
Alexandrova E, Sergieva S, Kostova P, et al. Ipsilateral in-breast tumor recurrence after breast conserving therapy: true recurrence versus new primary tumor. J BUON. 2015;20:1001-8PubMed
35.
Sarsenov D, Ilgun S, Ordu C, et al. True Local Recurrences after Breast Conserving Surgery have Poor Prognosis in Patients with Early Breast Cancer. Cureus. 2016;8:e541PubMedPubMedCentral
36.
Bright CJ, Rea DW, Francis A, et al. Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013. Cancer Epidemiol. 2016;44:186-194CrossRefPubMed
37.
Abner AL, Recht A, Eberlein T, et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol. 1993;11:44-8CrossRefPubMed
38.
Gentilini O, Botteri E, Veronesi P, et al. Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates. Ann Surg Oncol. 2012;19:3771-6CrossRefPubMed
39.
Arthur DW, Winter KA, Kuerer HM, et al. NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year toxicity report from a Phase 2 study of repeat breast-preserving surgery and 3-dimensional conformal partial-breast reirradiation for in-breast recurrence. Int J Radiat Oncol Biol Phys. 2017;98:1028-1035CrossRefPubMed
40.
Vicini FA, Antonucci JV, Goldstein N, et al. The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy. Cancer. 2007;109:1264-72CrossRefPubMed
41.
Bollet MA, Servant N, Neuvial P, et al. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. J Natl Cancer Inst. 2008;100:48-58CrossRefPubMed